Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis

DOI PDF 被引用文献5件
  • Jeanne E. Anderson
    From the Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System, Audie L. Murphy Division; both of San Antonio, TX; Hematology Division, Mayo Clinic, Rochester, MN; Clinical Research Division, Fred Hutchinson Cancer Research Center; University of Washington School of Medicine; Seattle Veterans Administration Hospital; both of Seattle, WA; and Hospital St Louis, Paris, France.
  • Ayalew Tefferi
    From the Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System, Audie L. Murphy Division; both of San Antonio, TX; Hematology Division, Mayo Clinic, Rochester, MN; Clinical Research Division, Fred Hutchinson Cancer Research Center; University of Washington School of Medicine; Seattle Veterans Administration Hospital; both of Seattle, WA; and Hospital St Louis, Paris, France.
  • Fiona Craig
    From the Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System, Audie L. Murphy Division; both of San Antonio, TX; Hematology Division, Mayo Clinic, Rochester, MN; Clinical Research Division, Fred Hutchinson Cancer Research Center; University of Washington School of Medicine; Seattle Veterans Administration Hospital; both of Seattle, WA; and Hospital St Louis, Paris, France.
  • Leona Holmberg
    From the Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System, Audie L. Murphy Division; both of San Antonio, TX; Hematology Division, Mayo Clinic, Rochester, MN; Clinical Research Division, Fred Hutchinson Cancer Research Center; University of Washington School of Medicine; Seattle Veterans Administration Hospital; both of Seattle, WA; and Hospital St Louis, Paris, France.
  • Thomas Chauncey
    From the Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System, Audie L. Murphy Division; both of San Antonio, TX; Hematology Division, Mayo Clinic, Rochester, MN; Clinical Research Division, Fred Hutchinson Cancer Research Center; University of Washington School of Medicine; Seattle Veterans Administration Hospital; both of Seattle, WA; and Hospital St Louis, Paris, France.
  • Frederick R. Appelbaum
    From the Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System, Audie L. Murphy Division; both of San Antonio, TX; Hematology Division, Mayo Clinic, Rochester, MN; Clinical Research Division, Fred Hutchinson Cancer Research Center; University of Washington School of Medicine; Seattle Veterans Administration Hospital; both of Seattle, WA; and Hospital St Louis, Paris, France.
  • Philippe Guardiola
    From the Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System, Audie L. Murphy Division; both of San Antonio, TX; Hematology Division, Mayo Clinic, Rochester, MN; Clinical Research Division, Fred Hutchinson Cancer Research Center; University of Washington School of Medicine; Seattle Veterans Administration Hospital; both of Seattle, WA; and Hospital St Louis, Paris, France.
  • Natalie Callander
    From the Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System, Audie L. Murphy Division; both of San Antonio, TX; Hematology Division, Mayo Clinic, Rochester, MN; Clinical Research Division, Fred Hutchinson Cancer Research Center; University of Washington School of Medicine; Seattle Veterans Administration Hospital; both of Seattle, WA; and Hospital St Louis, Paris, France.
  • Cesar Freytes
    From the Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System, Audie L. Murphy Division; both of San Antonio, TX; Hematology Division, Mayo Clinic, Rochester, MN; Clinical Research Division, Fred Hutchinson Cancer Research Center; University of Washington School of Medicine; Seattle Veterans Administration Hospital; both of Seattle, WA; and Hospital St Louis, Paris, France.
  • Yair Gazitt
    From the Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System, Audie L. Murphy Division; both of San Antonio, TX; Hematology Division, Mayo Clinic, Rochester, MN; Clinical Research Division, Fred Hutchinson Cancer Research Center; University of Washington School of Medicine; Seattle Veterans Administration Hospital; both of Seattle, WA; and Hospital St Louis, Paris, France.
  • Betty Razvillas
    From the Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System, Audie L. Murphy Division; both of San Antonio, TX; Hematology Division, Mayo Clinic, Rochester, MN; Clinical Research Division, Fred Hutchinson Cancer Research Center; University of Washington School of Medicine; Seattle Veterans Administration Hospital; both of Seattle, WA; and Hospital St Louis, Paris, France.
  • H. Joachim Deeg
    From the Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System, Audie L. Murphy Division; both of San Antonio, TX; Hematology Division, Mayo Clinic, Rochester, MN; Clinical Research Division, Fred Hutchinson Cancer Research Center; University of Washington School of Medicine; Seattle Veterans Administration Hospital; both of Seattle, WA; and Hospital St Louis, Paris, France.

抄録

<jats:title>Abstract</jats:title><jats:p>Current therapeutic options for myeloid metaplasia with myelofibrosis (MMM) are limited. A pilot study was conducted of autologous peripheral blood stem cell (PBSC) collection in 27, followed by transplantation in 21 patients with MMM. The median age was 59 (range 45-75) years. PBSCs were mobilized at steady state (n = 2), after granulocyte colony-stimulating factor (G-CSF) alone (n = 17), or after anthracycline-cytarabine induction plus G-CSF (n = 8). A median of 11.6 × 106 (range 0 to 410 × 106) CD34+ cells per kilogram were collected. Twenty-one patients then underwent myeloablation with oral busulfan (16 mg/kg) and PBSC transplantation. The median times to neutrophil and platelet recovery after transplantation were 21 (range 10-96) and 21 (range, 13 to ≥ 246) days, respectively. Five patients received back-up PBSC infusion because of delayed neutrophil or platelet recovery. The median follow-up is 390 (range 70-1623) days after transplantation, and the 2-year actuarial survival is 61%. After transplantion, 6 patients died: 3 of nonrelapse causes (1 within 100 days of PBSC infusion) and 3 of disease progression. Erythroid response (hemoglobin ≥ 100 g/L [10 gm/dL] without transfusion for ≥ 8 weeks) occurred in 10 of 17 anemic patients. Four of 8 patients with a platelet count less than 100 × 109/L (100 000/μL) responded with a durable platelet count more than 100 × 109/L (100 000/μL). Symptomatic splenomegaly improved in 7 of 10 patients. It is concluded that (1) PBSC collection was feasible and stable engraftment occurred after transplantation in most patients with MMM, (2) myeloablation with busulfan was associated with acceptable toxicity, (3) a significant proportion of patients derived clinical benefit after treatment, and (4) further investigation of this novel approach is warranted.</jats:p>

収録刊行物

  • Blood

    Blood 98 (3), 586-593, 2001-08-01

    American Society of Hematology

被引用文献 (5)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ